source
- A PureTech startup banks $180M for a new IPF drugCelea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.BioPharma Dive · 27d ago↗ source
- Roche KRAS drug succeeds in head-to-head lung cancer studyThe Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.BioPharma Dive · 27d ago↗ source
- FDA Approves First Gene Therapy for Young Children with Sickle Cell DiseaseThe U.S. Food and Drug Administration today issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged 2 years and older with either sickle cell disease (SCD) with recu…fda press · 27d ago